Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.

Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2328-9503 (Electronic) Linking ISSN: 23289503 NLM ISO Abbreviation: Ann Clin Transl Neurol Subsets: MEDLINE

Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc on behalf of American Neurological Association, [2014]-

Neuromyelitis Optica*/blood ; Neuromyelitis Optica*/cerebrospinal fluid ; Neuromyelitis Optica*/diagnosis ; Biomarkers*/blood ; Biomarkers*/cerebrospinal fluid ; Proteomics*/methods; Humans ; Female ; Adult ; Male ; Middle Aged ; CD56 Antigen/blood ; Aquaporin 4/immunology ; Aquaporin 4/blood

Objective: Neuromyelitis optica (NMO) was a serious autoimmune inflammatory condition affecting the central nervous system. Currently, there was a lack of diagnostic biomarkers for AQP4-IgG-negative NMO patients.
Methods: A comparative proteomic analysis was conducted on the CSF of 10 patients with NMO and 10 patients with non-inflammatory neurological disorders (NND) using tandem mass tagging technology. Differentially expressed proteins (DEPs) were analyzed using bioinformatic methods. The candidate proteins were then validated through ELISAs in a subsequent cohort of 160 samples, consisting of paired CSF and plasma samples from 50 NMO patients, CSF samples from 30 NND patients, and plasma samples from 30 healthy individuals.
Results: We identified 389 proteins via proteomics, screening 79 DEPs. NCAM1, SST and AHSG were selected as candidate molecules for further validation. Compared to NND patients, there were decreased levels of AHSG in CSF and increased levels of NCAM1 and SST in NMO patients. The ELISA results revealed significantly higher levels of AHSG, SST and NCAM1 in the CSF of the NMO group compared to the NND group. Similarly, the serum levels of these three proteins were also higher in the NMO group compared to the healthy control group. It was found that serum NCAM1 levels significantly decreased in patients with non-relapsed NMO compared to patients with relapsed NMO and CSF NCAM1 level increased in patients with bilateral NMO compared to patients with unilateral NMO. Furthermore, CSF SST levels increased in AQP4 antibody-positive NMO patients compared to AQP4 antibody-negative patients.
Interpretation: CSF NCAM1, serum NCAM1 and serum SST may serve as potential biomarkers for NMO patients and aid in the diagnosis of AQP4 antibody-negative NMO patients.
(© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)

Biol Pharm Bull. 2017;40(10):1630-1637. (PMID: 28966235)
Brain. 2023 Aug 1;146(8):3364-3372. (PMID: 36864689)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
PLoS One. 2022 Oct 7;17(10):e0268592. (PMID: 36206263)
Lancet Reg Health West Pac. 2020 Sep 06;2:100021. (PMID: 34327375)
Biol Psychiatry. 1999 Aug 15;46(4):551-6. (PMID: 10459406)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
J Alzheimers Dis. 2019;68(4):1667-1675. (PMID: 30958362)
Trends Neurosci. 1996 Nov;19(11):473-80. (PMID: 8931273)
J Immunol. 1996 Jul 15;157(2):679-88. (PMID: 8752917)
J Neuroinflammation. 2019 Dec 28;16(1):280. (PMID: 31883522)
Nat Rev Neurol. 2010 Jul;6(7):383-92. (PMID: 20639914)
Front Immunol. 2021 Jul 22;12:705536. (PMID: 34367165)
Bioinformatics. 2015 Feb 15;31(4):608-9. (PMID: 25677125)
Brain Res Brain Res Rev. 2001 Oct;36(2-3):175-84. (PMID: 11690614)
J Neuroinflammation. 2018 Oct 22;15(1):294. (PMID: 30348195)
Bioinformatics. 2011 Feb 1;27(3):431-2. (PMID: 21149340)
Neurochem Int. 2019 Oct;129:104518. (PMID: 31381945)
Mol Vis. 2009 Aug 19;15:1638-48. (PMID: 19710940)
Front Neurosci. 2020 Feb 19;14:96. (PMID: 32140092)
Neurol Neuroimmunol Neuroinflamm. 2015 Jun 18;2(4):e121. (PMID: 26140280)
Front Immunol. 2021 Aug 20;12:700031. (PMID: 34489947)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
J Neuroimmunol. 2017 Jan 15;302:49-55. (PMID: 27988051)
Nat Rev Dis Primers. 2020 Oct 22;6(1):85. (PMID: 33093467)
Neurology. 2015 Jul 14;85(2):177-89. (PMID: 26092914)
Curr Opin Cell Biol. 1997 Oct;9(5):627-34. (PMID: 9330865)
Lancet Neurol. 2022 Dec;21(12):1120-1134. (PMID: 36179757)
Lancet. 2004 Dec 11-17;364(9451):2106-12. (PMID: 15589308)
J Proteomics. 2020 Aug 15;225:103879. (PMID: 32585426)
Brain Pathol. 2013 Nov;23(6):661-83. (PMID: 24118483)
J Neuroinflammation. 2012 Jan 19;9:14. (PMID: 22260418)
Neuroimmunomodulation. 2010;17(3):177-9. (PMID: 20134196)
Metabolism. 1996 Aug;45(8 Suppl 1):86-7. (PMID: 8769392)
Biochem Pharmacol. 2013 Aug 15;86(4):497-507. (PMID: 23770458)
Clin Chim Acta. 2015 Feb 2;440:64-71. (PMID: 25444748)

2022-2-013 Beijing High-level Public Health Technical Personnel Training Programme; 7222052 Beijing Municipal Natural Science Foundation; DFL20220505 Beijing Hospitals Authority's Ascent Plan; BYESS2022170 Beijing Association for Science and Technology

Date Created: 20240301 Date Completed: 20240514 Latest Revision: 20240516

20240516

PMC11093237

10.1002/acn3.52033

38425144